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The most relevant comorbidities in patients with peripheral artery disease (PAD) are coronary artery disease (CAD) and diabetes
mellitus (DM). However, data of long-term follow-up of patients with chronic total occlusion (CTO) are scarce. The aim of the
study was to assess the impact of CAD and DM on long-term follow-up patients after superficial femoral artery (SFA) CTO
retrograde recanalization. In this study, eighty-six patients with PAD with diagnosed CTO in the femoropopliteal region and at
least one unsuccessful attempt of antegrade recanalization were enrolled in 2 clinical centers. Mean time of follow-up in all
patients was 47.5 months (±40 months). Patients were divided into two groups depending on the presence of CAD (CAD
group: n = 45 vs. non-CAD group: n = 41) and DM (DM group: n = 50 vs. non-DM group: n = 36). In long-term follow-up,
major adverse peripheral events (MAPE) occurred in 66.6% of patients with CAD vs. 36.5% of patients without CAD and in
50% of patients with DM vs. 55% of non-DM subjects. There were no statistical differences in peripheral endpoints in both
groups. However, there was a statistically significant difference in all-cause mortality: in the DM group, there were 6 deaths
(12%) (P value = 0.038). To conclude, patients after retrograde recanalization, with coexisting CTO and DM, are at higher risk
of death in long-term follow-up.
1. Introduction
Coexistence of peripheral artery disease (PAD), coronary
artery disease (CAD), and cerebrovascular disease causes
almost 2 million deaths in Europe each year [1]. There are
an increasing number of patients with PAD, who have
increased mortality rate and higher risk of cardiovascular
events; however, PAD is still underdiagnosed [2]. It is worth
pointing out that PAD is an independent risk factor for
increased cardiovascular mortality [1]. The most relevant
comorbidities in patients with PAD are CAD and diabetes
mellitus (DM) [3]. Patients with diagnosed DM are charac-
terized by higher frequency of PAD occurrence [4], and
DM itself accelerates the progression of atherosclerosis.
Recent studies have shown the impact of glycemia control
and severity of CAD on patency of peripheral arteries in
patients with PAD and poorer outcomes in long-term
follow-up [5]. Chronic total occlusion (CTO) affects around
50% of patients with PAD. Patients with CTO in the femor-
opopliteal region require complex treatment of PAD and
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comorbidities [1]. The most challenging cases in patients
with CTO are those with unsuccessful antegrade recanaliza-
tion (around 10-15%) [6]. Data of long-term follow-up of
patients with CTO are scarce. The aim of the study was to
assess the influence of CAD and DM on the long-term
follow-up in patients after superficial femoral artery (SFA)
CTO retrograde recanalization.
2. Material and Methods
We included 86 patients, enrolled in two centers, with
symptomatic PAD and diagnosed chronic total occlusion in
the artery of the lower extremity, after at least one attempt
of unsuccessful antegrade recanalization. CTO lesions were
verified in angiography of the lower extremities’ vessels.
Patients were screened for most relevant comorbidities
and risk factors. Before the procedure, all patients were
evaluated according to the Rutherford/Fontaine scale and
the ankle-brachial index (ABI) measurements were per-
formed. All patients were qualified for retrograde recanaliza-
tion, after previous unsuccessful antegrade crossing, and
registry description was previously published [7].
The procedure of retrograde recanalization was per-
formed according to the local protocol. Puncture was per-
formed under the guidance of ultrasound or fluoroscopy.
All patients required 2 approaches: proximal, mostly in the
femoral common artery, and distal, in the distal part of SFA
or the proximal part of the popliteal artery. A few patients
required procedures also in arteries below the knee.
After the index procedure, patients were administrated
dual antiplatelet therapy (75mg of aspirin, 75mg of clopido-
grel) for 1-3 months, low molecular weight heparin for 1
month, and high dose of statin.
Two separated analyses were performed based on the
presence of CAD and DM. Patients were divided into 2
groups: patients with diagnosed CAD and without CAD.
CAD was defined as previous acute coronary syndrome, his-
tory of percutaneous coronary intervention, bypass grafting
(CABG), or lesions in coronary arteries ≥ 50% stenosis eval-
uated in coronary angiography.
In the second analysis, patients were divided into 2
groups based on the presence of DM—patients with diag-
nosed DM and without DM. Patients were enrolled to the
DM group regardless of the type of treatment (diet, oral med-
ications, and insulin) and duration of DM. Patients with
newly diagnosed DM during index hospitalization were
excluded from analysis.
All patients were screened during clinical follow-up for
major adverse cardiac and cardiovascular events (MACCE),
major adverse peripheral events (MAPE), and all-cause
mortality.
MACCE was defined as acute coronary artery syndrome,
coronary artery intervention, coronary bypass grafting, and
stroke/transient ischemic attack (TIA).
MAPE was defined as target vessel reintervention, non-
target vessel reintervention, and amputation.
All patients were screened for all-cause deaths: cardiac
and noncardiac.
Regression analysis was performed to find independent
predictors for cardiac events, cerebrovascular events, periph-
eral events, and all-cause death in patients after CTO retro-
grade recanalization in the femoropopliteal region.
2.1. Statistical Analysis. Results are presented as the num-
ber of patients (percentage) or mean value ± standard devia-
tion (SD)/median value or interquartile range (IQR) where
applicable. Differences between groups were tested using
the Chi-square test and Fisher’s exact test for dichotomous
variables and the Mann-Whitney U test for continuous vari-
ables. The Kaplan-Meier method was used to assess the
difference in mortality during follow-up between patients.
Additionally, univariate Cox regression analysis was per-
formed. In all tests, P value of <0.05 was considered statisti-
cally significant.
3. Results
Mean time of long-term follow-up in all patients was 47.5
months (±40 months). Patients were divided into two groups
depending on the presence of CAD (CAD: n = 45 vs. non-
CAD: n = 41) and DM (DM: n = 50 vs. non-DM: n = 36). In
group DM vs. non-DM, the average age was similar. In both
groups, most of the patients were male. Diabetic patients
were treated with insulin, oral hypoglycemic medications,
or diet only. Details of medical history are presented in
Table 1. In long-term follow-up, MAPE was observed in
50% of patients with DM and 55.5% of patients without DM.
Target vessel revascularization, nontarget vessel revascu-
larization, stroke, acute coronary syndrome, and unsuccess-
ful revascularization were similar in both groups (Table 2).
The observed number of amputations in the DM group was
twofold higher than that in the group without DM, but it
was not statistically significant. The all-cause mortality rate
was higher in the DM group (12% vs. none, P = 0 038,
Figure 1). In Cox regression analysis, DM was an indepen-
dent risk factor for death (P = 0 0147).
In the CAD/no-CAD cohort, the number of patients in
both groups was similar. The mean age of patients were
66.7 (±11.8) in the CAD group and 75 years (±14.1) in the
non-CAD group. Both groups were comparable in terms of
the presence of comorbidities. All demographics and medical
history are presented in Table 1.
In long-term follow-up, reinterventions in the target
vessel were observed in 27% of the CAD group and in
6% of the non-CAD group. All endpoints are presented
in Table 2. MAPE occurred in 66.6% of patients with CAD
and in 36.5% of patients without CAD. There was no signif-
icant difference in all endpoints in both groups (Table 3 and
Figure 2).
4. Discussion
PAD is an atherosclerotic disease and becomes an increasing
problem in elderly population. PAD alone is associated with
a higher rate of mortality and morbidity, including cerebro-
vascular events, as compared to the mortality and morbidity
rate of patients without PAD [2, 8, 9]. Moreover, PAD shares
2 Journal of Diabetes Research
similar risk factors with CAD [10, 11] and patients with
comorbid PAD and CAD reach worse outcomes in follow-
up than patients with CAD alone [12, 13].
Around 50% of patients with diagnosed symptomatic
PAD suffer from CTO [6]. Despite the development of
numerous endovascular techniques, CTO lesions in the
femoropopliteal region are still challenging for endovascular
treatment and those patients required complex treatment.
Retrograde recanalization of SFA CTO in patients with at
least one unsuccessful antegrade crossing is a safe and effec-
tive option with a patency rate at 88.2% after one year [14]
and an amputation rate 4.7% in long-term follow-up [7].
The mortality rate in follow-up varies between 6.9% and
23% [7, 15], and the patency rate of the target vessel in critical
limb ischemia is up to 42% [16]. However, additional data
from long-term follow-up after retrograde recanalization is
still limited.
In our study, we confirmed that DM has a relevant
impact on long-term outcomes in patients after retrograde
revascularization of the femoropopliteal region. Cooccur-
rence of PAD and DM reaches more than 30% [17]. In
Table 2: Major adverse cardiac and cerebrovascular events (MACCE) and other events after SFA CTO revascularization stratified by DM
presence.
All patients (n = 86) DM (n = 50) Non-DM (n = 36) P value
TVR (n, %) 18 (20.9) 9 (18) 9 (25) 0.4
Non-TVR (n, %) 23 (26.7) 13 (26) 10 (27.8) 0.8
Amputation (n, %) 4 (4.6) 3 (6) 1 (2.8) 0.8
Stroke (n, %) 0 0 0
ACS (n, %) 3 (3.5) 2 (4) 1 (2.8) 0.8
All-cause mortality (n, %) 6 (6.9) 6 (12) 0 0.038
Unsuccessful revascularization (n, %) 5 (5.8) 2 (4) 3 (8.3) 0.6
ACS: acute coronary syndrome; CTO: chronic total occlusion; SFA: superficial femoral artery; non-TVR: nontarget vessel revascularization; TVR: target vessel
revascularization.
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Figure 1: Kaplan-Meier survival curve in group DM vs. non-DM.
DM: diabetes mellitus.
Table 1: Demographics and medical history of patients in the DM/non-DM group and CAD/non-CAD group.
All patients (n = 86) DM (n = 50) Non-DM (n = 36) P value CAD (n = 45) Non-CAD (n = 41) P value
Mean age, years (±SD) 65 (±9) 65 (±8.9) 62 (±10.1) 0.57 67 (±11.8) 75 (±14.1) 0.19
Sex (male, n, %) 58 (67.4) 33 (60) 25 (69) 0.51 28 (62) 29 (70) 0.39
BMI (kg/m2) (±SD) 29 (±5.9) 31 26 0.4 28 30 0.51
Hypertension (n, %) 75 (87) 45 (90) 30 (83) 0.55 40 (88.8) 35 (85) 0.64
DM (n, %) 50 (58.1) 0.8
(i) Insulin 21 (42) 12 (26.6) 10 (24.4) 0.9
(ii) Oral 28 (56) 14 (31) 13 (31) 0.95
(iii) Diet only 1 (2) 1 (2) 0
(iv) Non-DM 0 36 (100) 18 (40) 18 (43.9) 0.87
CAD (n, %) 45 (52.3) 28 (56) 17 (47) 0.56 45 (100) 0
COPD (n, %) 11 (12.8) 7 (14) 4 (11) 0.3 7 (15.5) 4 (9) 0.42
Hypercholesterolemia (n, %) 52 (60.5) 27 (54) 25 (69) 0.1 27 (60) 25 (62) 0.79
Previous stroke/TIA (n, %) 8 (9.3) 5 (10) 3 (8) 0.85 4 (8) 4 (9) 0.89
Smoking (n, %) 38 (44.2) 21 (42) 17 (47) 0.54 18 (40) 20 (48.7) 0.24
BMI: body mass index; CAD: coronary artery disease; COPD: chronic obstructive pulmonary disease; DM: diabetes mellitus; SD: standard deviation: TIA:
transient ischemic attack.
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patients with coexisting PAD and DM, there is greater sever-
ity of PAD, which can be explained by the higher rate of
amputation in this population (DM 41.4% vs. non-DM
11.5%) [18]. This trend can be seen also in our study, where
the amputation rate was twice lower in the non-DM group.
Additionally, the mortality rate in DM patients is twice
higher (51.7% vs. 25.6%) than that in non-DM patients
[18]. These findings were confirmed by Reiber et al. who
pointed out that 5-year mortality in diabetic patients with
PAD reaches 50% and overall amputation risk is up to 20%
[19]. Our results stay in accordance with previously pub-
lished data where the mortality rate among patients with
coexisting PAD and DM is higher and statistically relevant
(12% vs. 0, P value = 0.038). Moreover, Jude et al. reported
that in a diabetic deceased group of patients, there was a
trend toward higher prevalence of CTO in arteries [18].
According to the study by Leibson et al., coexistence of
PAD and DM increases risk of death 1.67 times compared
to PAD alone and 1.55 times compared to DM alone [2].
On the other hand, Weis-Müller et al. suggested that
at 1-, 3-, and 5-year of follow-up, limb salvage rates were
not influenced by DM or CAD and 1-, 3-, and 5-year survival
was uninfluenced by DM alone, though CAD reduced life
expectancy [20].
In patients with PAD, the prevalence of CAD reaches
between 46 and 71% [21, 22].
Previous studies point out that PAD is associated with
higher rate of cardiovascular adverse events (5.35% vs.
4.52%) [23] and higher rate of total mortality in long-term
observation (47.8% vs. 36.4%) than CAD [13]. In analysis
of patients who underwent vascular surgery, postoperative
and long-term outcomes are determined by CAD [24, 25].
In a group of patients with lower limb reconstruction proce-
dures, the main causes of 30-day mortality were cardiovascu-
lar events and infections [25]. Results from our study show
higher frequency of amputations and mortality rate in the
group of patients with diagnosed CAD. It is also worth point-
ing out that patients with CAD are characterized by a twofold
rise in the reintervention rate in the previous treated lesion.
Although results are not statistically significant, it shows a
trend of increased tendency of adverse events, including
MAPE, in long-term follow-up.
What is more, recent studies show comparison differ-
ences between reducing risk factors in patients with CAD
and PAD. Patients with CAD are more intensively treated
for atherosclerotic risk factors than PAD patients [25, 26].
Administration of hypolipemic drugs was higher in patients
with hypercholesterolemia and CAD than in patients with
high cholesterol level and PAD (58% vs. 46%) [26].
Our study confirmed that most of the results from stud-
ies designed for the general population of patients with
PAD can be extrapolated to a subgroup of patients after
retrograde recanalization of the femoropopliteal region.
Coexistence of DM in those patients is correlated with
higher all-cause mortality rate in long-term follow-up,
although the amputation rate and TVR revascularization
were uninfluenced by DM or CAD. However, the expected
impact of CAD on MACCE and MAPE was not confirmed
in this study. The study group included a small number of
selected patients with CTO and unsuccessful antegrade
recanalization. Patients with CAD were on average 10 years
younger than the non-CAD group, which could have influ-
enced the results. What is more, the study was planned as a
retrospective registry which may be considered limitation;
for example, data about duration of DM and level of glyce-
mia control were not collected.
Table 3: Major adverse cardiac and cerebrovascular events (MACCE) and other events after SFA CTO recanalization stratified by CAD
presence.
All patients (n = 86) CAD (n = 45) Non-CAD (n = 41) P value
TVR (n,%) 18 (20.9) 12 (27) 6 (14.6) 0.2
Non-TVR (n,%) 23 (26.7) 15 (33) 8 (19.5) 0.2
Amputation (n,%) 4 (4.6) 3 (6.6) 1 (2.4) 0.36
Stroke (n,%) 0 0 0
ASC (n,%) 3 (3.5) 1 (2.2) 2 (4.9) 0.6
All-cause mortality (n,%) 6 (6.9) 4 (8.9) 2 (4.9) 0.68
Unsuccessful revascularization (n,%) 5 (5.8) 2 (4.4) 3 (7.3) 0.7
ACS: acute coronary syndrome; CTO: chronic total occlusion; SFA: superficial femoral artery; non-TVR: nontarget vessel revascularization; TVR: target vessel
revascularization.
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Figure 2: Kaplan-Meier survival curve in group CAD vs. non-CAD.
CAD: coronary artery disease.
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5. Conclusion
Patients, after retrograde femoropopliteal recanalization,
with coexisting CTO and DM, are at higher risk of death than
non-DM patients. Despite our previous study, we do not
confirm the impact of CAD on the long-term follow-up in
patients with PAD. However, complex treatment of those
patients should be focused on intensively reducing athero-
sclerotic risk factors.
Data Availability
All external data used in this paper are listed in References.
Conflicts of Interest
All authors listed meet the authorship criteria according
to the latest guidelines of the International Committee of
Medical Journal Editors. The authors declare that there is
no conflict of interest.
Authors’ Contributions
All authors agree with the contents of the manuscript.
References
[1] C. Stehouwer, D. Clement, C. Davidson et al., “Peripheral arte-
rial disease: a growing problem for the internist,” European
Journal of Internal Medicine, vol. 20, no. 2, pp. 132–138, 2009.
[2] C. Leibson, J. Ransom, W. Olson, B. R. Zimmerman, W. M.
O'Fallon, and P. J. Palumbo, “Peripheral arterial disease, diabe-
tes, and mortality,” Diabetes Care, vol. 27, no. 12, pp. 2843–
2849, 2004.
[3] H. Lawall, C. Diehm, U. Hoffmann, and H. Reinecke, “Update
PAVK: epidemiology, comorbidity and prognosis of periph-
eral arterial obstructive disease,” Deutsche Medizinische
Wochenschrift, vol. 140, no. 24, pp. 1798–1802, 2015.
[4] P. Norman, W. Davis, D. Bruce, and T. M. E. Davis, “Periph-
eral arterial disease and risk of cardiac death in type 2 diabe-
tes,” Diabetes Care, vol. 29, no. 3, pp. 575–580, 2006.
[5] L. Harris and M. Dryjski, “Epidemiology, risk factor, and nat-
ural history of peripheral artery disease,” May 2016, http://
www.uptodate.com/contents/epidemiology-risk-factors-and-
natural-history-of-peripheral-artery-disease.
[6] L. L. Nadal, J. Cynamon, E. C. Lipsitz, andA. Bolia, “Subintimal
angioplasty for chronic arterial occlusions,” Techniques in Vas-
cularand InterventionalRadiology, vol. 7, no. 1, pp. 16–22, 2004.
[7] Z. Ruzsa, J. Wojtasik-Bakalarz, A. Nyerges, T. Rakowski,
P. Kleczynski, and S. Bartus, “Long-term follow-up after retro-
grade recanalization of superficial femoral artery chronic total
occlusion,” The Journal of Invasive Cardiology, vol. 29, no. 10,
pp. 336–339, 2017.
[8] M. Criqui, J. Denenberg, R. Langer, and A. Fronek, “The epide-
miology of peripheral arterial disease: importance of identify-
ing the population at risk,” Vascular Medicine, vol. 2, no. 3,
pp. 221–226, 1997.
[9] M. Criqui, R. Langer, A. Fronek et al., “Mortality over a period
of 10 years in patients with peripheral arterial disease,” The
New England Journal of Medicine, vol. 326, no. 6, pp. 381–
386, 1992.
[10] P. Poredoš and B. Jug, “The prevalence of peripheral arterial
disease in high risk subjects and coronary or cerebrovascular
patients,” Angiology, vol. 58, no. 3, pp. 309–315, 2007.
[11] D. L. Bhatt, P. G. Steg, E. M. Ohman et al., “International
prevalence, recognition, and treatment of cardiovascular risk
factors in outpatients with atherothrombosis,” JAMA, vol. 295,
no. 2, pp. 180–189, 2006.
[12] B. A. Golomb, T. T. Dang, and M. H. Criqui, “Peripheral arte-
rial disease: morbidity and mortality implications,” Circula-
tion, vol. 114, no. 7, pp. 688–699, 2006.
[13] S. Subherwal, M. R. Patel, L. Kober et al., “Peripheral artery
disease is a coronary heart disease risk equivalent among both
men and women: results from a nationwide study,” European
Journal of Preventive Cardiology, vol. 22, no. 3, pp. 317–325,
2015.
[14] J. Wojtasik-Bakalarz, S. Arif, M. Chyrchel et al., “Twelve
months follow-up after retrograde recanalization of superficial
femoral artery chronic total occlusion,” Advances in Interven-
tional Cardiology, vol. 13, no. 1, pp. 47–52, 2017.
[15] Z. Ruzsa, B. Nemes, Z. Bánsághi et al., “Transpedal access after
failed anterograde recanalization of complex below-the-knee
and femoropoliteal occlusions in critical limb ischemia,” Cath-
eterization and Cardiovascular Interventions, vol. 83, no. 6,
pp. 997–1007, 2014.
[16] C.Walker, “Pedal access in critical limb ischemia,” The Journal
of Cardiovascular Surgery, vol. 55, no. 2, pp. 225–227, 2014.
[17] A. T. Hirsch, M. H. Criqui, D. Treat-Jacobson et al.,
“Peripheral arterial disease detection, awareness, and treat-
ment in primary care,” JAMA, vol. 286, no. 11, pp. 1317–
1324, 2001.
[18] E. Jude, S. Oyibo, N. Chalmers, and A. J. M. Boulton, “Periph-
eral arterial disease in diabetic and nondiabetic patients a com-
parison of severity and outcome,” Diabetes Care, vol. 24, no. 8,
pp. 1433–1437, 2001.
[19] G. Reiber, R. Pecoraro, and T. Koepsell, “Risk factors for
amputation in patients with diabetes mellitus: a case-control
study,” Annals of Internal Medicine, vol. 117, no. 2, pp. 97–
105, 1992.
[20] B. Weis-Müller, V. Römmler, I. Lippelt et al., “Critical chronic
peripheral arterial disease: does outcome justify crural or pedal
bypass surgery in patients with advanced age or with comor-
bidities?,” Annals of Vascular Surgery, vol. 25, no. 6, pp. 783–
795, 2011.
[21] R. Sukhija, W. Aronow, K. Yalamanchili, N. Sinha, and
S. Babu, “Prevalence of coronary artery disease, lower
extremity peripheral arterial disease, and cerebrovascular dis-
ease in 110 men with an abdominal aortic aneurysm,” The
American Journal of Cardiology, vol. 94, no. 10, pp. 1358-
1359, 2004.
[22] R. Dieter, J. Tomasson, T. Gudjonsson et al., “Lower extremity
peripheral arterial disease in hospitalized patients with coro-
nary artery disease,” Vascular Medicine, vol. 8, no. 4,
pp. 233–236, 2003.
[23] P. G. Steg, D. L. Bhatt, P. W. F. Wilson et al., “One-year cardio-
vascular event rates in outpatients with atherothrombosis,”
JAMA, vol. 297, no. 11, pp. 1197–1206, 2007.
[24] M. Back, F. Leo, D. Cuthbertson, B. L. Johnson, M. L.
ShamesMD, and D. F. Bandyk, “Long-term survival after vas-
cular surgery: specific influence of cardiac factors and implica-
tions for preoperative evaluation,” Journal of Vascular Surgery,
vol. 40, no. 4, pp. 752–760, 2004.
5Journal of Diabetes Research
[25] G.Welten, O. Schouten, S. E. Hoeks et al., “Long-term progno-
sis of patients with peripheral arterial disease: a comparison in
patients with coronary artery disease,” Journal of the American
College of Cardiology, vol. 51, no. 16, pp. 1588–1596, 2008.
[26] M. McDermott, S. Mehta, H. Ahn, and P. Greenland, “Athero-
sclerotic risk factors are less intensively treated in patients with
peripheral arterial disease than in patients with coronary
artery disease,” Journal of General Internal Medicine, vol. 12,
no. 4, pp. 209–215, 1997.
6 Journal of Diabetes Research
Stem Cells 
International
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
MEDIATORS
INFLAMMATION
of
Endocrinology
International Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
Disease Markers
Hindawi
www.hindawi.com Volume 2018
BioMed 
Research International
Oncology
Journal of
Hindawi
www.hindawi.com Volume 2013
Hindawi
www.hindawi.com Volume 2018
Oxidative Medicine and 
Cellular Longevity
Hindawi
www.hindawi.com Volume 2018
PPAR Research
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2013www.hindawi.com
The Scientific 
World Journal
8
Immunology Research
Hindawi
www.hindawi.com Volume 2018
Journal of
Obesity
Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
 Computational and  
Mathematical Methods 
in Medicine
Hindawi
www.hindawi.com Volume 2018
Behavioural 
Neurology
Ophthalmology
Journal of
Hindawi
www.hindawi.com Volume 2018
Diabetes Research
Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
Research and Treatment
AIDS
Hindawi
www.hindawi.com Volume 2018
Gastroenterology 
Research and Practice
Hindawi
www.hindawi.com Volume 2018
Parkinson’s 
Disease
Evidence-Based 
Complementary and
Alternative Medicine
Volume 2018
Hindawi
www.hindawi.com
Submit your manuscripts at
www.hindawi.com
